Ironwood Pharmaceuticals, Inc.
IRWD
$0.5341
-$0.0603-10.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.05% | -22.98% | -19.47% | -12.09% | -28.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.05% | -22.98% | -19.47% | -12.09% | -28.05% |
| Cost of Revenue | 6.26% | -32.43% | -9.02% | 53.65% | 100.94% |
| Gross Profit | -72.05% | -4.41% | -23.70% | -26.94% | -46.21% |
| SG&A Expenses | -35.49% | -28.48% | 11.65% | 15.77% | 20.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.49% | -31.69% | 1.24% | 30.36% | 44.25% |
| Operating Income | -192.07% | 1.13% | -47.23% | -51.01% | -80.94% |
| Income Before Tax | -831.59% | -20.97% | -45.61% | 101.75% | -92.47% |
| Income Tax Expenses | -87.79% | -32.29% | -23.68% | 48.88% | -54.73% |
| Earnings from Continuing Operations | -798.27% | 229.28% | -73.86% | 99.92% | -109.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -798.27% | 307.54% | -76.20% | 99.92% | -109.10% |
| EBIT | -192.07% | 1.13% | -47.23% | -51.01% | -80.94% |
| EBITDA | -184.13% | 1.03% | -45.92% | -51.06% | -80.18% |
| EPS Basic | -779.55% | 301.43% | -76.81% | 99.92% | -108.92% |
| Normalized Basic EPS | -421.50% | -5.98% | -60.28% | -80.43% | -91.97% |
| EPS Diluted | -674.00% | 274.07% | -77.27% | 99.92% | -111.96% |
| Normalized Diluted EPS | -421.50% | -5.98% | -52.52% | -80.43% | -90.29% |
| Average Basic Shares Outstanding | 2.08% | 2.20% | 2.45% | 2.35% | 2.10% |
| Average Diluted Shares Outstanding | 2.08% | 2.20% | -14.26% | 2.35% | -15.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |